Entering the European market is not easy. Up to 51 countries with different healthcare systems. What is your strategy?
Our work consists of supporting companies that want to introduce pharmaceuticals in our part of Europe. Let us work together, and Let us commercialise your pharmaceuticals. For the benefit of the patient.
We manage, through our logistic partners with their regional warehouses, the distribution to our region (28 countries). They have the capability to handle the most demanding of specialized product order management, storage, handling and distribution requirements.
You know that market research is critical. It provides customer insights, competitive intelligence, behavioural tendencies, and product positioning. And market research increasingly is becoming an important component for linking R&D and marketing teams.
Achieving reimbursement and getting the right price are the 2 most important drivers for a successful launch of an innovative pharmaceuticals in our part of Europe. Health Authorities in any European country decide individually based on their local regulations, policies, framework, social values and available health care budget.
Unlike other regions, in the EU a number of options is available to obtain a marketing authorisation. Centralised at the European Medicines Agency in Amsterdam or decentralised with the individual competent authorities of the member states, each marketing authorisation application procedure has its pros and cons. In the case of Switzerland, it has its own regulatory authority, Swissmedic, and processes.
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.
Entering the European market is not easy. Up to 51 countries with different healthcare systems. What is your strategy? Apart from the Big-5, what do you do with the other 28 countries? We offer a solution for 28 countries. Sales and marketing is our core business.
We know these local markets, and this gives you the best opportunity for commercialising your specialized (niche) pharmaceuticals. 1 single point of contact gives you the possibility to have your products available to 200 million Europeans in 28 countries. For all 28 countries or a selection of these countries.